Led · Equity · Jan 2026

KAHR Bio is a clinical-stage biotechnology company based in Modi’in, Israel that creates dual-targeting fusion protein therapeutics designed to activate both the innate and adaptive immune systems within the tumor microenvironment. Its lead candidate, DSP107, is a first-in-class bispecific CD47×4-1BB T-cell engager that anchors to CD47-expressing tumor cells while delivering a potent 4-1BB co-stimulatory signal to recruit and activate cytotoxic T cells. Across more than 130 treated patients, DSP107 has shown a favorable safety and tolerability profile. In a Phase 2a study of heavily pre-treated metastatic microsatellite stable colorectal cancer (MSS-CRC), DSP107 combined with atezolizumab achieved a 17.5-month median overall survival, outperforming the 6.4–10.8 months generally seen with approved therapies, even though 75% of patients had liver metastases. Encouraged by these data, the company has launched a randomized, controlled Phase 2b trial comparing DSP107 plus atezolizumab to fruquintinib in fourth-line MSS-CRC, with interim results expected in late 2026 and topline data in the second half of 2027. Proceeds from its latest financing and an accompanying debt facility are intended to fully fund this Phase 2b program and other R&D activities.

Participated · Series B · Jul 2025

Restore Medical is a clinical-stage MedTech company based in Or Yehuda, Israel, developing novel minimally invasive transcatheter therapies for heart failure. Its core product is a transcatheter device intended to restore hemodynamic balance and improve clinical outcomes for patients with limited effective treatment options. The company reports promising long-term safety and efficacy from its European feasibility study, including meaningful improvements in ventricular reverse remodeling, hemodynamic performance, and patient functional capacity. Restore Medical received Breakthrough Device Designation from the U.S. Food and Drug Administration in 2024. The $23M Series B will fund completion of the ongoing European feasibility study and support the launch of a U.S.-based clinical study. The company was co-founded by Stephen Bellomo (CTO), Dr. Elchanan Bruckheimer (Medical Director), and Aaron Feldman, began operations within Peregrine Ventures' Incentive Incubator, and is led by CEO Gilad Marom.

Participated · Equity · Jan 2025

Lutris Pharma is a clinical-stage biopharmaceutical company focused on improving anti-cancer therapy effectiveness by reducing cutaneous dose-limiting toxicity. Its lead asset, LUT014, is a topical B‑Raf inhibitor designed to treat EGFR inhibitor–induced acneiform rash and potentially allow patients to continue EGFRi therapy. LUT014 completed enrollment in an international phase 2 trial in metastatic colorectal cancer patients in October 2024, and the company expects to report top-line results in the first half of 2025 at a major medical meeting. Lutris also successfully completed a phase 1/2 study of LUT014 for radiation-induced dermatitis in breast cancer patients. The company aims to provide novel topical therapies to mitigate dermal side effects, improve quality of life, and enable adherence to anti-cancer regimens. Lutris Pharma is based in Tel Aviv, Israel. The company recently secured financing to advance the clinical development of LUT014.

Participated · Equity · Apr 2024

Variantyx develops proprietary, clinically-accredited whole genome analysis platforms for genetic disorders, reproductive health, and precision oncology. The company reports sequencing tens of thousands of genomes to date. It has seen a rapid increase in test volumes in Q1 2024 and is expanding its market share as demand shifts from panel and exome testing to whole genome testing. Variantyx says it maintains strong unit economics while aiming to provide genome-based care to a larger number of patients. The company plans ongoing innovation of new genome analysis technologies and will use new capital for technological and commercial expansion. Variantyx is based in Framingham, Mass., and has attracted more than $125 million in total investment to date. Variantyx develops a proprietary whole-genome analysis platform that provides advanced genomic testing for rare genetic disorders, reproductive health, and precision oncology. Its precision oncology solution combines multiple genomic technologies to identify tumor-specific genetic alterations to help predict therapy response, optimize management, and provide prognostic and clinical-trial information. The company says its platform offers unmatched diagnostic capabilities and improved personalized treatment recommendations. Variantyx is targeting growth in North America and Europe, which it cites as key regions for precision medicine spending. Management intends to scale commercial efforts to take advantage of the growing global precision medicine market. The company recently strengthened its capital position through a debt financing to support that growth. Variantyx is a technology-driven precision medicine company based in Framingham, Mass., providing advanced genomic testing for rare genetic disorders, reproductive health, and precision oncology. The company has developed proprietary whole genome analysis platforms that enable clinicians and patients to understand a person’s genetic makeup. These platforms aim to improve diagnostic capabilities and support personalized treatment recommendations. Led by CEO Haim Neerman, Variantyx provides solutions across diagnostics and oncology markets. The company raised $41.5M in a Series C-2 to accelerate growth and bring newly developed solutions to market. Variantyx plans to focus the investment on expanding its precision oncology offerings while scaling across its other target markets. Variantyx provides Genomic Unity, a WGS-based single-method testing program that identifies multiple variant types from a single patient sample and issues a unified clinical report. The company’s WGS methodology is used to diagnose rare inherited and neurological disorders and is being positioned as a first-line test to reduce the diagnostic odyssey. Variantyx has also announced a WGS-based prenatal test for high-risk pregnancies with ultrasound anomalies. The company recently secured $20M in Series C funding to extend its technology into comprehensive tumor diagnostic solutions and to expand sales. Management says the funding will enable faster diagnosis and implementation of personalized treatment plans for cancer patients. Variantyx operates as a high-complexity hereditary disease testing laboratory under CLIA/CAP.

Participated · Series C · Jan 2024

Bluewhite builds retrofittable autonomous robots sold as a robots-as-a-service offering that can operate existing tractors. It develops both hardware (branded Pathfinder) and a service/data stack (branded Compass) that use AI, computer vision, and big-data analytics to deliver autonomous operation and field insights. The system can be installed in one day as an "IKEA kit" at local service centers, and retrofitted tractors remain operable by humans when needed. Customers range from small family farms to 20 of the largest year-round permanent crop growers in the U.S., with strongest traction in California and Washington. Bluewhite's robots have cumulatively logged 50,000 hours of autonomous farming across 150,000 acres, and customers typically subscribe on five-year contracts. The company plans to invest the new funding into R&D for Compass and Pathfinder and to expand in current and new markets to address labor shortages and improve asset utilization. Blue White Robotics develops an autonomous farm platform that delivers Robots-as-a-Service (RaaS), retrofitting existing farming infrastructure with intelligent autonomous algorithms. Its robot tractors perform tasks including spraying, harvesting, disking, and seeding while improving productivity, precision, and worker safety. The platform collects and distributes operational data to create new services aimed at increasing yields and reducing inputs. The company says it will use the new funding to accelerate adoption, expand U.S. sales, and attract key talent for its international team. Blue White Robotics emphasizes values of "Fellowship, Love of the land, and Innovation" in its mission to revolutionize agriculture through autonomy. The company has received $50M of investment since its inception in 2017. Blue White Robotics provides an autonomy platform that integrates multiple robot types, including aerial drones, autonomous tractors, and driverless shuttles. Rather than building its own autonomy stack, the company focuses on "autonomy now," enabling customers to manage fleets of heterogeneous robots through a single platform and a management console designed for non-technical users such as farmers and hospital administrators. In agriculture the company sells after-market autonomy kits that let farmers put existing tractors onto its platform and supports large growers with aerial spraying for pollination and crop care. Blue White Robotics aims to complement other autonomous vehicle and drone companies by providing orchestration, data collection, and vendor/customer workflows rather than competing directly. The company has raised $10 million in funding and employs about 75 people. Its vehicles run autonomous shuttles at Bar Ilan University and Tel HasShomer Hospital and were used in 2020 to deliver COVID-19 equipment, samples, and tests.